Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Open Label Study to Evaluate the Safety, Tolerability and Immunogenicity of PENNVAX-B (Gag, Pol, Env) + Electroporation in HIV-1 Infected Adult Participants.

Next Previous
Search
Trial Profile

A Phase I, Open Label Study to Evaluate the Safety, Tolerability and Immunogenicity of PENNVAX-B (Gag, Pol, Env) + Electroporation in HIV-1 Infected Adult Participants.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 08 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 06 Jan 2015 Results published in an Inovio Pharmaceuticals media release and in the journal Molecular Therapy.
  • 13 Mar 2012 Interim results published in an Inovio Pharmaceuticals media release.
  • 09 Dec 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top